TABLE 1.
Eligibility criteria for this systematic review.
| Inclusion | Exclusion | |
|---|---|---|
| Participant | Patients diagnosed with psoriasis vulgaris. No limitations relating to gender, age, race, economic status, or education | Patients without psoriasis vulgaris |
| Intervention | Patients with psoriasis vulgaris have received CHMIs interventions, such as Buguzhi injection, Danshen injection, Huangqi injection, and Qingkailing injection | Patients with psoriasis vulgaris have not been treated with CHMIs, or the studies’ findings did not wholly reflect the clinical effect of CHMIs |
| Patients could be treated with CHMIs alone or combined with other conventional therapies (phototherapy, acitretin capsule, etc.) in the intervention group | ||
| In addition, the therapy could involve no treatments, placebo, or conventional therapies in the control group | ||
| Outcome | The primary outcome of this study is the Psoriasis Area and Severity Index (PASI) score, and the secondary outcome includes the effective rate and the adverse effects | Studies with incomplete data or data errors |
| Study design | • Observational studies | |
| • Reviews | ||
| • Consensus-based studies | ||
| • Randomized controlled trials | • Commentaries | |
| • Conference abstracts | ||
| • Case reports | ||
| • Animal or cell experiments |